--- title: "Viatris (VTRS) news: class action, offering and merger" url: "https://aibio.space/companies/viatris/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VTRS class action, offering and merger news: Viatris faces Indore plant securities class action and derivative suits in two federal courts. Viatris Inc." --- VTRS Viatris Inc. NASDAQ · United States # Viatris (VTRS) news VTRS class action, offering and merger news Mergers · 2026-10-08 ## [Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash](https://aibio.space/news/viatris-agrees-acquire-pacira-biosciences-36-50-share-cash/) Viatris agreed to buy Pacira for $36.50 a share in cash, an equity value of $1.65 billion, through a tender offer and a second-step merger. The release states no premium to the recent share price. ## Latest Viatris news 1. 2026-08-06 Legal [Viatris faces Indore plant securities class action and derivative suits in two federal courts](https://aibio.space/news/viatris-faces-indore-plant-securities-class-action-derivative-suits/) Viatris (Nasdaq: VTRS) and unnamed current and former officers are defendants in a Pennsylvania class action over Indore disclosures. Derivative suits name officers and directors in Pennsylvania and Delaware. 2. 2026-07-01 Debt Financing [Viatris closes ¥40,000,000,000 unsecured term loan with Mizuho Bank](https://aibio.space/news/viatris-closes-40-000-000-000-unsecured-term-loan-mizuho-bank/) Viatris signed a ¥40,000,000,000 senior unsecured term loan with Mizuho Bank, Ltd. as administrative agent. The proceeds may repay a 2021 loan of the same size, and the company reported a net loss of $3.51 billion for 2025. 3. 2026-06-18 Debt Financing [Viatris completes €650,000,000 public offering of 4.250% senior notes due 2033](https://aibio.space/news/viatris-completes-650-000-000-public-offering-4-250-percent-senior/) Viatris completed a €650,000,000 offering of 4.250% senior notes due 2033 on June 17, 2026. The proceeds first repay June revolver borrowings used to pay off $1.675 billion of 2026 notes, and the company reported a 2025 net loss of $3.51 billion. The 8-K names no underwriter. 4. 2026-06-12 Debt Financing [Viatris offers €650,000,000 of 4.250% senior notes due 2033](https://aibio.space/news/viatris-offers-650-000-000-4-250-percent-senior-notes-due-2033/) Viatris is offering €650,000,000 of 4.250% senior notes due 2033 to repay revolving credit borrowings drawn to retire its 2026 notes. Its 2025 net loss was $3.51 billion. 5. 2026-02-26 Distress [Viatris expects $700 million to $850 million in restructuring charges, plans up to 10% staff cut](https://aibio.space/news/viatris-expects-700-million-850-million-restructuring-charges-plans-up/) After an enterprise-wide strategic review, Viatris committed to restructuring that it expects to cut its global workforce by up to approximately 10%. It expects potential savings of between $600 million and $700 million. ## Viatris at a glance - **Ticker**: VTRS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $886.5 million ### Related companies - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) NASDAQ: PYXS - [Damora Therapeutics](https://aibio.space/companies/damora-therapeutics/) NASDAQ: DMRA - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [Madrigal Pharmaceuticals](https://aibio.space/companies/madrigal-pharmaceuticals/) NASDAQ: MDGL - [Werewolf Therapeutics](https://aibio.space/companies/werewolf-therapeutics/) NASDAQ: HOWL - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) NASDAQ: SRPT - [Capricor Therapeutics](https://aibio.space/companies/capricor-therapeutics/) NASDAQ: CAPR ### Also on NASDAQ - [Avalo Therapeutics](https://aibio.space/companies/avalo-therapeutics/) AVTX - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) PBLS - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) SLDB - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) KLRS - [Korro Bio](https://aibio.space/companies/korro-bio/) KRRO - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) PHVS ## What Viatris does Viatris is a global healthcare company that supplies generics, including complex products, globally recognized brands and an expanding portfolio of innovative medicines. It operates in more than 165 countries and territories, with 27 manufacturing, packaging and distribution sites and more than 1,400 approved molecules. Its 2025 total revenues were $14.30 billion. The company reported five positive Phase 3 data readouts in 2025. These included MR-107A-02, a fast-absorbing formulation of meloxicam for moderate-to-severe acute pain, LYNX-2 for MR-142 (phentolamine ophthalmic solution) in night driving impairment, and VEGA-3 for MR-141 in presbyopia, whose supplemental NDA was accepted in February 2026. A low-dose estrogen weekly dermal patch has an NDA accepted under the FDA's 505(b)(2) pathway with a target action date of July 30, 2026. Other pipeline assets include selatogrel and cenerimod, which remain on track for enrollment. Viatris also received the first approval for Inpefa (sotagliflozin) in the United Arab Emirates and launched it in early 2026. Its Iron Sucrose Injection launched in the U.S. in 2025. | Product or program | What it is | Stage | |---|---|---| | MR-107A-02 (meloxicam) | Fast-absorbing meloxicam for moderate-to-severe acute pain | positive Phase 3 top-line results | | Low-dose estrogen weekly dermal patch | Contraceptive patch with norelgestromin and ethinyl estradiol | NDA accepted; target action date July 30, 2026 | | MR-141 (phentolamine ophthalmic solution) | Treatment for presbyopia | supplemental NDA accepted February 2026; FDA action expected in the second half of 2026 | | MR-142 (phentolamine ophthalmic solution) | Treatment for chronic night driving impairment in keratorefractive patients | positive Phase 3 LYNX-2 results | | Inpefa (sotagliflozin) | Medicine for markets outside the U.S. and Europe | first approval in the United Arab Emirates; launched early 2026 | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm). ## Viatris annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$14.30 billion](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | [$14.74 billion](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | | Net income (loss) | [-$3.51 billion](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | [-$634.2 million](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | | Cash from operations | [$2.32 billion](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | [$2.30 billion](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | | Cash and equivalents | [$1.32 billion](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/) | [$734.8 million](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | | Short-term investments | [$40.7 million](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | [$38.0 million](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $886.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Viatris Is there a class action against Viatris? Our latest story on this, dated Aug 6, 2026: "Viatris faces Indore plant securities class action and derivative suits in two federal courts". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/viatris-faces-indore-plant-securities-class-action-derivative-suits/). Has Viatris raised money recently? Our latest story on this, dated Jun 18, 2026: "Viatris completes €650,000,000 public offering of 4.250% senior notes due 2033". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/viatris-completes-650-000-000-public-offering-4-250-percent-senior/). Is Viatris involved in a merger or acquisition? Our latest story on this, dated Oct 8, 2026: "Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/viatris-agrees-acquire-pacira-biosciences-36-50-share-cash/). What is the ticker symbol of Viatris? Viatris Inc. trades under the ticker VTRS on NASDAQ. Where is Viatris listed? Viatris Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:VTRS; BMV:VTRS; DUS:VIA; EUROTLX:4VTRS; FWB:VIA; GETTEX:VIA; HAM:VIA; HAN:VIA; LS:A2QAME; LSIN:0A5V; LSX:A2QAME; MUN:VIA; SIX:VTRS; SWB:VIA; TRADEGATE:VIA; VIE:VTRS; XETR:VIA. What is the SEC CIK of Viatris? The SEC Central Index Key (CIK) for Viatris Inc. is 1792044. Its filings are on SEC EDGAR. How many shares does Viatris have outstanding? 1,148,590,864 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Viatris listed under? Our directory records Viatris Inc. under United States. What does Viatris do? Our directory classifies Viatris Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Viatris? The ISIN recorded for Viatris Inc. is US92556V1061. Does aibio.space cover Viatris? aibio.space lists Viatris Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Viatris incorporated? SEC records list its state or country of incorporation as DE. What does Viatris develop? Viatris is a global healthcare company that supplies generics, including complex products, globally recognized brands and an expanding portfolio of innovative medicines. It operates in more than 165 countries and territories, with 27 manufacturing, packaging and distribution sites and more than 1,400 approved molecules. What is MR-107A-02 (meloxicam) from Viatris? MR-107A-02 (meloxicam): Fast-absorbing meloxicam for moderate-to-severe acute pain Stage: positive Phase 3 top-line results. What is Low-dose estrogen weekly dermal patch from Viatris? Low-dose estrogen weekly dermal patch: Contraceptive patch with norelgestromin and ethinyl estradiol Stage: NDA accepted; target action date July 30, 2026. ## Investor discussion: Viatris Members talk about Viatris (VTRS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Viatris, newest first. Each line links the filing it comes from. 1. 2026-10-08 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1792044/000114036126039024/ef20083514_ex99-1.htm) 2. 2026-06-12 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1792044/000114036126024994/ny20068251x1_424b5.htm) 3. 2026-02-26 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm) 4. 2025-05-08 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000018/vtrs-20250331.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VTRS on TradingView](https://www.tradingview.com/symbols/NASDAQ-VTRS/). ## SEC filings and registration - **SEC name**: Viatris Inc - **CIK**: 1792044 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: VTRS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 1000 MYLAN BOULEVARD, CANONSBURG, PA, 15317 - **Phone**: (724) 514-1465 - **Shares outstanding**: 1,148,590,864 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Upjohn Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1792044/000114036126039024/ef20083514_8k.htm) filed 2026-10-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/vtrs-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1792044/000114036126027216/ef20077152_8k.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1792044/000114036126025744/ef20076340_8k.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1792044/000114036126025228/ef20076197_8k.htm) filed 2026-06-15 - [424B5](https://www.sec.gov/Archives/edgar/data/1792044/000114036126025215/ny20068251x4_424b5.htm) filed 2026-06-15 - [424B5](https://www.sec.gov/Archives/edgar/data/1792044/000114036126024994/ny20068251x1_424b5.htm) filed 2026-06-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001792044), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Viatris Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VTRS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Viatris Inc. - **Ticker**: VTRS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US92556V1061 - **Other listed symbols**: BIVA:VTRS; BMV:VTRS; DUS:VIA; EUROTLX:4VTRS; FWB:VIA; GETTEX:VIA; HAM:VIA; HAN:VIA; LS:A2QAME; LSIN:0A5V; LSX:A2QAME; MUN:VIA; SIX:VTRS; SWB:VIA; TRADEGATE:VIA; VIE:VTRS; XETR:VIA - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VTRS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/viatris/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Viatris (VTRS) news: class action, offering and merger", 2026-10-31, https://aibio.space/companies/viatris/